Search

Displaying results 5651 - 5660 of 6831 in total
  1. Drug

    Lofepramine

    go.drugbank.com/drugs/DB13411
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  2. Drug

    Imipramine oxide

    go.drugbank.com/drugs/DB13782
    Experimental

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  3. Drug

    Imidacloprid

    go.drugbank.com/drugs/DB11421
    ExperimentalVet approved

    Imidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise

  4. Drug

    Urelumab

    go.drugbank.com/drugs/DB12077
    Investigational

    The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with

  5. Drug

    LV-SMENP Vaccine

    go.drugbank.com/drugs/DB15804
    Experimental

    LV-SMENP-DC is a vaccine candidate being developed by Shenzhen Geno-Immune Medical Institute that comprises dendritic cells that are modified with lentiviral vector-expressing synthetic minigene which … This vaccine is also administered with antigen-specific cytotoxic T lymphocytes (CTLs). As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials.

  6. Drug

    Tirapazamine

    go.drugbank.com/drugs/DB04858
    Investigational

    It is important to take into consideration that normally, the cells in these hypoxic regions are resistant to radiotherapy and most anticancer drugs.

  7. Drug

    Oxyphencyclimine

    go.drugbank.com/drugs/DB00383
    Approved

    Oxyphencyclimine is an anticholinergic drug (trade name Daricon) used in treating peptic ulcers.

  8. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria. Bruton's tyrosine kinase plays a role in B cell r...

  9. Drug

    Sodium copper chlorophyllin

    go.drugbank.com/drugs/DB16522
    Investigational

    SCC of the commercial-grade is prepared from a reaction between a crude chlorophyll extract and methanolic sodium hydroxide, followed by replacement of the central magnesium atom with a heavy metal[A227718

  10. Drug

    Telapristone acetate

    go.drugbank.com/drugs/DB05253
    Investigational

    Telapristone acetate, an orally-available, selective progesterone receptor modulator, is in development to alleviate symptoms associated with both uterine fibroids and endometriosis.